4.6 Article

3C Protease of Enterovirus D68 Inhibits Cellular Defense Mediated by Interferon Regulatory Factor 7

Journal

JOURNAL OF VIROLOGY
Volume 90, Issue 3, Pages 1613-1621

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.02395-15

Keywords

-

Categories

Funding

  1. 973 Project [2011CB504903]
  2. National Science Foundation for Outstanding Young Scientists [81225014]
  3. Program for Changjiang Scholars and Innovative Research Team in University [IRT13007]
  4. National Institute of Allergy and Infectious Diseases of the United States [AI112755]

Ask authors/readers for more resources

Human enterovirus 68 (EV-D68) is a member of the EV-D species, which belongs to the EV genus of the Picornaviridae family. Over the past several years, clusters of EV-D68 infections have occurred worldwide. A recent outbreak in the United States is the largest one associated with severe respiratory illness and neurological complication. Although clinical symptoms are recognized, the virus remains poorly understood. Here we report that EV-D68 inhibits innate antiviral immunity by downregulation of interferon regulatory factor 7 (IRF7), an immune factor with a pivotal role in viral pathogenesis. This process depends on 3C(pro), an EV-D68-encoded protease, to mediate IRF7 cleavage. When expressed in host cells, 3C(pro) targets Q167 and Q189 within the constitutive activation domain, resulting in cleavage of IRF7. Accordingly, wild-type IRF7 is fully active. However, IRF7 cleavage abrogated its capacity to activate type I interferon expression and limit replication of EV-D68. Notably, IRF7 cleavage strictly requires the protease activity of 3C(pro). Together, these results suggest that a dynamic interplay between 3C(pro) and IRF7 may determine the outcome of EV-D68 infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Infectious Diseases

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity Comment

Dafna Yahav, Dana Yelin, Isabella Eckerle, Christiane S. Eberhardt, Jianwei Wang, Bin Cao, Laurent Kaiser

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Article Medicine, General & Internal

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study (Publication with Expression of Concern. See vol. 401, pg. 90, 2023)

Chaolin Huang, Lixue Huang, Yeming Wang, Xia Li, Lili Ren, Xiaoying Gu, Liang Kang, Li Guo, Min Liu, Xing Zhou, Jianfeng Luo, Zhenghui Huang, Shengjin Tu, Yue Zhao, Li Chen, Decui Xu, Yanping Li, Caihong Li, Lu Peng, Yong Li, Wuxiang Xie, Dan Cui, Lianhan Shang, Guohui Fan, Jiuyang Xu, Geng Wang, Ying Wang, Jingchuan Zhong, Chen Wang, Jianwei Wang, Dingyu Zhang, Bin Cao

Summary: This study aimed to investigate the long-term health consequences of discharged COVID-19 patients and associated risk factors, particularly disease severity. Patients with more severe illness during hospitalization showed more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, highlighting the need for targeted interventions for long-term recovery.

LANCET (2021)

Article Multidisciplinary Sciences

The Rhinolophus affinis bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2

Pei Li, Ruixuan Guo, Yan Liu, Yingtao Zhang, Jiaxin Hu, Xiuyuan Ou, Dan Mi, Ting Chen, Zhixia Mu, Yelin Han, Zihan Chen, Zhewei Cui, Leiliang Zhang, Xinquan Wang, Zhiqiang Wu, Jianwei Wang, Qi Jin, Zhaohui Qian

Summary: Bat coronavirus RaTG13 shares high genome similarity with SARS-CoV-2 and uses human ACE2 for entry. Various animal ACE2s, including Rhinolophus affinis bat ACE2, can act as entry receptors for SARS-CoV-2 and RaTG13. Mutagenesis analysis identified critical residues in spike proteins for recognition of host ACE2. These findings contribute to understanding coronavirus entry, host range, and virus-host coevolution.

SCIENCE BULLETIN (2021)

Article Multidisciplinary Sciences

TRIM26 is a critical host factor for HCV replication and contributes to host tropism

Yisha Liang, Guigen Zhang, Qiheng Li, Lin Han, Xiaoyou Hu, Yu Guo, Wanyin Tao, Xiaomin Zhao, Mingzhe Guo, Tianyu Gan, Yimin Tong, Yongfen Xu, Zhuo Zhou, Qiang Ding, Wensheng Wei, Jin Zhong

Summary: Through a genome-wide CRISPR-Cas9 screening, the study identified E3 ligase TRIM26 as a critical host factor for HCV replication, with its deficiency impairing HCV genome replication. Mechanistic studies revealed that TRIM26 mediates the ubiquitination of HCV-encoded NS5B protein and promotes HCV genome replication, while the unique structure of mouse TRIM26 prevents its support for HCV replication, unlike human TRIM26 which can promote HCV infection.

SCIENCE ADVANCES (2021)

Article Immunology

SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation

Wenjing Wang, Zhuo Zhou, Xia Xiao, Zhongqin Tian, Xiaojing Dong, Conghui Wang, Li Li, Lili Ren, Xiaobo Lei, Zichun Xiang, Jianwei Wang

Summary: The study found that SARS-CoV-2 nsp12 suppresses host antiviral responses by attenuating specific IFN promoter activation and impacting the function of IRF3. These findings provide new insights into the viral pathogenesis.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Letter Medicine, General & Internal

SARS-CoV-2's origin should be investigated worldwide for pandemic prevention

Zhiqiang Wu, Qi Jin, Guizhen Wu, Jian Lu, Mingkun Li, Deyin Guo, Ke Lan, Luzhao Feng, Zhaohui Qian, Lili Ren, Wenjie Tan, Wenbo Xu, Weizhong Yang, Jianwei Wang, Chen Wang

LANCET (2021)

Article Biology

Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry

Shiyou Zhu, Ying Liu, Zhuo Zhou, Zhiying Zhang, Xia Xiao, Zhiheng Liu, Ang Chen, Xiaojing Dong, Feng Tian, Shihua Chen, Yiyuan Xu, Chunhui Wang, Qiheng Li, Xuran Niu, Qian Pan, Shuo Du, Junyu Xiao, Jianwei Wang, Wensheng Wei

Summary: The outbreak of COVID-19 caused by SARS-CoV-2 has led to a global health crisis. Through genome-wide screening, novel host factors (LDLRAD3, TMEM30A, and CLEC4G) have been identified as functional receptors for SARS-CoV-2, playing critical roles in infection.

SCIENCE CHINA-LIFE SCIENCES (2022)

Article Multidisciplinary Sciences

The architecture of the SARS-CoV-2 RNA genome inside virion

Changchang Cao, Zhaokui Cai, Xia Xiao, Jian Rao, Juan Chen, Naijing Hu, Minnan Yang, Xiaorui Xing, Yongle Wang, Manman Li, Bing Zhou, Xiangxi Wang, Jianwei Wang, Yuanchao Xue

Summary: Researchers have used vRIC-seq technology to reveal the tertiary structure of the SARS-CoV-2 genome in virions, finding an unentangled globule conformation. They also discovered the role of long-range duplexes and higher-order junctions in the sequential packaging of the viral genome, with some mutations potentially contributing to more stable duplex structures.

NATURE COMMUNICATIONS (2021)

Article Multidisciplinary Sciences

MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes

Xiaoman Liu, Fengwen Xu, Lili Ren, Fei Zhao, Yu Huang, Liang Wei, Yingying Wang, Conghui Wang, Zhangling Fan, Shan Mei, Jingdong Song, Zhendong Zhao, Shan Cen, Chen Liang, Jianwei Wang, Fei Guo

Summary: MARCH8 acts as an important player in the host anti-influenza virus defense by targeting M2 protein and inhibiting viral replication. The discovery that H1N1 influenza A virus has evolved to resist MARCH8-mediated ubiquitination and degradation sheds light on the inhibitory effects of MARCH8 on virus transmission within the human population.

NATURE COMMUNICATIONS (2021)

Article Chemistry, Medicinal

Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp

Jianyuan Zhao, Yongxin Zhang, Minghua Wang, Qian Liu, Xiaobo Lei, Meng Wu, SaiSai Guo, Dongrong Yi, Quanjie Li, Ling Ma, Zhenlong Liu, Fei Guo, Jianwei Wang, Xiaoyu Li, Yucheng Wang, Shan Cen

Summary: Three compounds were identified to exhibit remarkable potency in inhibiting RNA synthesis driven by SARS-CoV-2 RdRp, showing potential for drug development against COVID-19.

ACS INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Targeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity

Chi Zhang, Weiyun Li, Xiaobo Lei, Zhenfei Xie, Linlin Qi, Hui Wang, Xia Xiao, Jun Xiao, Yuxiao Zheng, Chen Dong, Xin Zheng, Shiyang Chen, Jianfeng Chen, Bing Sun, Jun Qin, Qiwei Zhai, Jinsong Li, Bin Wei, Jianwei Wang, Hongyan Wang

Summary: The study reveals that in viral infection, LPA suppresses interferon production through the LPA1 receptor, affecting immune responses. Additionally, LPA1 and ROCK1/2 may impact viral infections by promoting vascular leaking or lung fibrosis. Therefore, targeting the LPA1-ROCK module could be beneficial for treating SARS-CoV-2 or other virus infections.

SCIENCE ADVANCES (2021)

Article Cell Biology

Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2

Shaojun Zhang, Wenze Huang, Lili Ren, Xiaohui Ju, Mingli Gong, Jian Rao, Lei Sun, Pan Li, Qiang Ding, Jianwei Wang, Qiangfeng Cliff Zhang

Summary: Comparative analysis revealed common and virus-specific host responses, identifying vRNA-associated proteins that either promote or restrict viral infection. The study highlighted how SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize vRNA and enhance viral translation. Interactome-informed drug repurposing led to the identification of potential broad-spectrum antivirals, including Cepharanthine and Trifluoperazine, with efficacy against the emerging SARS-CoV-2 B.1.351 variant.

CELL RESEARCH (2022)

Article Biochemistry & Molecular Biology

An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity

Yuehui Zhang, Limin Shang, Jing Zhang, Yuchen Liu, Chaozhi Jin, Yanan Zhao, Xiaobo Lei, Wenjing Wang, Xia Xiao, Xiuyuan Zhang, Yujiao Liu, Linlin Liu, Meng-Wei Zhuang, Qingkun Mi, Chunyan Tian, Jianwei Wang, Fuchu He, Pei-Hui Wang, Jian Wang

Summary: The study systematically investigates the interactions between 29 viral proteins and human cells, revealing key proteins involved in SARS-CoV-2 infection. It identifies the membrane protein ITGB1 as a mediator of viral entry and uncovers proteins that inhibit the interferon pathway. The research proposes potential drugs for COVID-19 treatment and provides valuable insights into viral infection mechanisms.

CELL CHEMICAL BIOLOGY (2022)

Article Medicine, General & Internal

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Lixue Huang, Qun Yao, Xiaoying Gu, Qiongya Wang, Lili Ren, Yeming Wang, Ping Hu, Li Guo, Min Liu, Jiuyang Xu, Xueyang Zhang, Yali Qu, Yanqing Fan, Xia Li, Caihong Li, Ting Yu, Jiaan Xia, Ming Wei, Li Chen, Yanping Li, Fan Xiao, Dan Liu, Jianwei Wang, Xianguang Wang, Bin Cao

Summary: The study aimed to compare the health outcomes and sequelae symptoms between 6 months and 12 months after discharge among COVID-19 survivors. Most survivors had good physical and functional recovery during the 1-year follow-up, but their health status at 12 months was still lower than that of the control population.

LANCET (2021)

Article Immunology

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

Danwei Yu, Yuanmei Zhu, Tao Jiao, Tong Wu, Xia Xiao, Bo Qin, Huihui Chong, Xiaobo Lei, Lili Ren, Sheng Cui, Jianwei Wang, Yuxian He

Summary: The study identified the critical role of the membrane-proximal external region (MPER) sequence of SARS-CoV-2 spike fusion protein in viral infectivity and developed novel lipopeptides with significantly improved inhibitory activity against SARS-CoV-2 fusion and infection. The new inhibitors also showed potent activity against emerging SARS-CoV-2 variants and cross-inhibited other human CoVs. Structural characterization revealed the mechanisms underlying the high binding and inhibition of the new inhibitors, providing important insights for peptide therapeutics development against SARS-CoV-2 and other CoVs.

EMERGING MICROBES & INFECTIONS (2021)

No Data Available